Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer
Conditions: ASCVD; Atherosclerotic Cardiovascular Disease; Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor; Cancer Interventions: Drug: Evolocumab; Drug: Statin Sponsors: Xiang Xie; Xinjiang Medical University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Cardiology | Cholesterol | Heart | Research | Statin Therapy | Study